First-in-Human Single and Multiple Dose of GLPG1690

NCT02179502 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG1690 single ascending doses
DRUG: Placebo single ascending doses
DRUG: GLPG1690, multiple ascending doses, oral suspension
DRUG: Placebo, multiple ascending doses, oral suspension

Sponsor

Lakefront Biotherapeutics NV